Posted by Michael Wonder on 26 Feb 2019
Bausch + Lomb announces FDA approval of Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38% for the treatment of post-operative inflammation and pain following ocular surgery
25 February 2019 - Lotemax SM is formulated with SubMicron technology for efficient penetration to key ocular tissues.
Bausch + Lomb today announced that the U.S. FDA has approved Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, a new gel formulation for the treatment of post-operative inflammation and pain following ocular surgery. Compared to Lotemax gel (loteprednol etabonate ophthalmic gel) 0.5%, Lotemax SM delivers a submicron particle size for faster drug dissolution in tears.
Lotemax SM also provides two times greater penetration to the aqueous humour compared to Lotemax gel.
